PATH, in collaboration with the Epidemiology & Disease Control Division, Government of Nepal, and B.P. Koirala Institute of Health Sciences, Dharan, is implementing a focused pharmacovigilance program for kala-azar, or visceral leishmaniasis (VL), in Nepal. The program aims to strengthen patient safety and care associated with the use of VL drugs. The results of the pharmacovigilance activities are summarized in this newsletter.
Corporate author(s): Epidemiology & Disease Control Division, Department of Health Services, Ministry of Health, Government of Nepal; B.P. Koirala Institute of Health Sciences, Dharan; PATH
Publication date: May 2016
934 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
This publication is part of the series Pharmacovigilance newsletters
Related regions: Asia
See also: Drug Development > Drug development
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA